Dedicated teleradiology services could expand quality healthcare in regions where access and staffing shortages hinder patient care the most. 

Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma.

The model incorporates specific data from MRI exams with patient risk factors to predict whether a person is likely to develop clinically significant prostate cancer.

Contextualized reports differ from structured reports in that they focus on specific clinical indications, rather than a basic standardized checklist of anatomical regions that does not always address a particular concern.

The model was developed and validated specifically for liver, spleen and pancreas segmentation, and outperformed a publicly available segmentation model already in use.